Compare Global X Uranium ETF (URA) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Uranium ETF vs GeneDx Holdings Corp — how do they compare? Global X Uranium ETF trades at $38.79 (market cap $5.48B), while GeneDx Holdings Corp trades at $67.29 (market cap $2.02B). The key difference: Global X Uranium ETF is far larger — about 2.7× GeneDx Holdings Corp's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Uranium ETF for 62 Days and GeneDx Holdings Corp for 19 Days on average.
| URA | WGS | |
|---|---|---|
Market Cap | $5.48B | $2.02B |
Volume | 5,287,170 | 734,640 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $61.81 | $167.51 |
52-Week Low | $37.52 | $34.51 |
Typical Hold Time | 62 Days | 19 Days |
Enterprise Value | — | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URA (Global X Uranium ETF) trades at $38.90, down 2.58% with a bearish technical signal. The ETF faces pressure from recent uranium sector volatility despite positive long-term nuclear energy demand drivers. Key support levels cluster around $37-38 while resistance sits at $39-41. Recent news highlights both opportunities from AI power demand growth and risks from sector-specific headwinds.
The uranium sector faces near-term volatility but benefits from structural tailwinds including AI power demand and global nuclear expansion. Investment opportunities exist through diversified uranium exposure, though risks include commodity price sensitivity and regulatory uncertainty. Current technical weakness suggests cautious entry points may emerge near support levels.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
